Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase ...
The company announced positive Phase 1 results for a subcutaneous formulation of Briumvi, evaluating it against the currently ...
A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer ...
CHENNAI: The four-member inquiry committee — headed by Dr N Baskar, medical superintendent, Rajiv Gandhi Government General ...
They witnessed their father suffering with physical and psychological distress and these final memories stay with them' ...
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE ...
Astria Therapeutics (ATXS) announced results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart, a monoclonal antibody inhibitor of plasma ...
As weight loss medications containing active ingredients like semaglutide continue to define a new chapter in metabolic ...
Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal ...
TG Therapeutics said its phase 1 study of subcutaneous Briumvi generated data that support the quarterly dosing regimen now ...
Wegovy is a medication typically prescribed for weight loss and cardiovascular risk reduction individuals with overweight or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results